FORM 4

UNITED STATES SECURITIES AND EXCHANGE COMMISSION

Washington, D.C. 20549

_			
STATEMENT	OF CHANGES	IN BENEFICIAL	OWNERSHIP

ı	OMB APPROVAL										
	OMB Number:	3235-0287									
l	Estimated average burden										
ı	hours per response:	0.5									

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934 or Section 30(h) of the Investment Company Act of 1940

1. Name and Address of Reporting Person* MALFROY-CAMINE BERNARD					2. Issuer Name and Ticker or Trading Symbol EYEGATE PHARMACEUTICALS INC EYEG]						[(Ch	Relationship of Reporting Person(s) to Issuer (Check all applicable)					
				E								X Director			10% Owner		
(Last)	(Fi	irst)	(Middle)			4 F!:4	T		- /D /\/\		_	Officer below)	(give title		Other (specification)	pecify	
C/O EYEGATE PHARMACEUTICALS, INC.					3. Date of Earliest Transaction (Month/Day/Year) 02/01/2019												
271 WAVERLEY OAKS ROAD, SUITE 108				L	02/01/2013												
					4. If Amendment, Date of Original Filed (Month/Day/Year)							6. Individual or Joint/Group Filing (Check Applicable					
(Street)											Line	,	ll l O	D	ti		
WALTH	AM M	A	02452										led by One led by More		•		
(City)	(Si	tate)	(Zip)									reisui					
Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned																	
Date			Transactior te onth/Day/Yo	Execution Date,		Code (Ins				Beneficia Owned F	s ally ollowing	Form:	Direct C Indirect E tr. 4)	7. Nature of Indirect Beneficial Ownership			
						Code V	Amount	(A) or (D)	Price	Reported Transact (Instr. 3 a	tion(s)		((Instr. 4)			
	Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)																
1. Title of Derivative Security (Instr. 3)	or Exercise (Month/Day/Year) if any Co		, Transa Code (ansaction of		6. Date Exercisable and Expiration Date (Month/Day/Year)		7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4)		8. Price of Derivative Security (Instr. 5)	9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4)		10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)			
				Code	v	(A)	(D)	Date Exercisable	Expiration Date	Title	Amount or Number of Shares						
Stock Option (right to buy)	\$0.48	02/01/2019		A		50,000		(1)	02/01/2029	Common Stock	50,000	\$0	50,000		D		

Explanation of Responses:

1. The Reporting Person received an Option to purchase Common Stock from the Issuer pursuant to the Issuer's 2014 Equity Incentive Plan. The Option will become exercisable as to 100% of the shares underlying the Option on February 1, 2020.

/s/ Robert A. Petitt, Attorneyin-Fact, Signed under power of attorney on behalf of Reporting

02/05/2019

Person

** Signature of Reporting Person D

 $Reminder: Report \ on \ a \ separate \ line \ for \ each \ class \ of \ securities \ beneficially \ owned \ directly.$

- * If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
- ** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).

Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.

Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.